Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

57
Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
57
Hepatitis01:25

Hepatitis

80
Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver.
80
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

22
Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion...
22
Subviral Agents01:29

Subviral Agents

927
Subviral agents are infectious entities that resemble viruses but lack one or more viral components, such as a capsid or essential replication machinery. These agents include viroids, prions, and satellites, each possessing distinct structural and functional characteristics that influence their mode of infection and replication.Viroids are the simplest subviral agents, consisting of circular, single-stranded RNA molecules without a protein coat. They exclusively infect plants, relying entirely...
927
Inhibitors of Bacterial DNA Synthesis01:28

Inhibitors of Bacterial DNA Synthesis

125
Bacterial pathogens depend on precise and efficient DNA replication to sustain infection. Two type II topoisomerases—DNA gyrase and topoisomerase IV—are critical to this process, as they resolve DNA supercoiling and unlink chromosomes during replication. Fluoroquinolones, synthetic derivatives of quinolones, exploit this mechanism by stabilizing the transient DNA–enzyme cleavage complex, preventing strand religation, and causing lethal double-strand breaks. These...
125
Inhibitors of Bacterial Protein Synthesis01:25

Inhibitors of Bacterial Protein Synthesis

102
Aminoglycosides constitute a highly potent class of bactericidal antibiotics that exert their antimicrobial effects by targeting the bacterial ribosome, specifically disrupting protein synthesis. These polycationic molecules consist of amino-modified sugars linked via glycosidic bonds to an aminocyclitol core such as 2-deoxystreptamine or streptamine. Their strong positive charges facilitate tight binding to the negatively charged phosphate backbone of ribosomal RNA (rRNA), primarily at the 16S...
102

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Safety, pharmacokinetics and pharmacodynamics of NXC736, a novel sphingosine-1-phosphate receptor modulator.

British journal of clinical pharmacology·2026
Same author

The nuclear cap-binding complex safeguards stress-resistant protein synthesis and proliferation of stem cells.

Science advances·2026
Same author

Well-Dispersed Entropy-Driven Alloy Particles on Carbon Black From Stepwise Alloying Strategy and Their Bifunctional Electrocatalytic Performance for Zinc-Air Batteries.

Small (Weinheim an der Bergstrasse, Germany)·2026
Same author

Biological sex modulates lung injury severity in adolescent mice exposed to short-term aerosolized vitamin E acetate.

Physiological reports·2025
Same author

Regulatory roles of long non-coding RNAs in minipigs revealed by cross-breed and cross-tissue transcriptomic analyses.

Scientific reports·2025
Same author

Ultra-Sensitive Aptamer-Based Diagnostic Systems for Rapid Detection of All SARS-CoV-2 Variants.

International journal of molecular sciences·2025

Related Experiment Video

Updated: Apr 28, 2026

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

2.2K

Potent Hepatitis C Virus NS5A Inhibitors Containing a Benzidine Core.

Il Hak Bae1, Jin Kyu Choi1, Chieyeon Chough1

  • 1Department of Chemistry, College of Natural Sciences, Seoul National University , Seoul 151-747, South Korea.

ACS Medicinal Chemistry Letters
|June 6, 2014
PubMed
Summary

Researchers discovered a novel hepatitis C virus (HCV) inhibitor, compound 6, with high potency and no toxicity. This benzidine prolinamide derivative shows promise as an effective drug candidate for treating HCV infections.

Keywords:
HCVNS5A inhibitorantiviral agentbenzidinestructure−activity relationship

More Related Videos

A Protocol for Analyzing Hepatitis C Virus Replication
13:04

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

23.7K
Reverse Genetics to Engineer Positive-Sense RNA Virus Variants
15:49

Reverse Genetics to Engineer Positive-Sense RNA Virus Variants

Published on: June 9, 2022

1.6K

Related Experiment Videos

Last Updated: Apr 28, 2026

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

2.2K
A Protocol for Analyzing Hepatitis C Virus Replication
13:04

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

23.7K
Reverse Genetics to Engineer Positive-Sense RNA Virus Variants
15:49

Reverse Genetics to Engineer Positive-Sense RNA Virus Variants

Published on: June 9, 2022

1.6K

Area of Science:

  • Medicinal Chemistry
  • Virology
  • Drug Discovery

Background:

  • Hepatitis C virus (HCV) infection remains a significant global health concern.
  • Development of effective antiviral therapies targeting HCV is crucial.

Purpose of the Study:

  • To discover and develop novel potent inhibitors of the HCV NS5A protein.
  • To identify a promising drug candidate for hepatitis C treatment.

Main Methods:

  • Synthesis of novel benzidine prolinamide derivatives.
  • Optimization of inhibitor structures, focusing on the capping group.
  • Evaluation of anti-HCV activity and cytotoxicity of synthesized compounds.

Main Results:

  • A series of potent HCV NS5A inhibitors were identified.
  • Compound 6 demonstrated highly potent anti-HCV activity.
  • Compound 6 exhibited no cytotoxicity, indicating a favorable safety profile.

Conclusions:

  • Compound 6, based on the benzidine prolinamide scaffold, is a potent and non-toxic inhibitor of HCV NS5A.
  • The novel inhibitor structure allows for easy modification and optimization.
  • Compound 6 is a promising drug candidate for the treatment of hepatitis C.